Targeting Sig-1R is identified as a potential drug repurposing approach to treat COVID-19 patients that, unlike virus-targeted antiviral agents, addresses adaptive cellular mechanisms of host cells that are crucial for viral infection. The gene discussed is SIGMAR1; the disease is viral infectious disease.